Use of natriuretic peptide for treating heart failure

US7732406B2 · kind B2 · utility

Assignee

• Cardiopep Pharma GmbH · DE

Inventors

• Veselin Mitrovic · Bad Nauheim, DE
• Hartmut Luss · Hannover, DE
• Wolf-Georg Forssmann · Hannover, DE
• Markus Meyer · Hannover, DE
• Klaus Dohler · Hannover, DE

Key dates

• Filing date: Apr 7, 2006
• Grant date: Jun 8, 2010
• Expiry date: Nov 17, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.